Announcements

Announcements

 

Paul G. Allen Frontiers Group [to 7 Nov 2020]
https://alleninstitute.org/what-we-do/frontiers-group/news-press/
News
No new digest content identified.

 

BARDA – U.S. Department of HHS [to 7 Nov 2020]
https://www.phe.gov/about/barda/Pages/default.aspx
BARDA News
No new digest content identified.

 

BMGF – Gates Foundation [to 7 Nov 2020]
http://www.gatesfoundation.org/Media-Center/Press-Releases
Press Releases and Statements
No new digest content identified.

 

Bill & Melinda Gates Medical Research Institute [to 7 Nov 2020]
https://www.gatesmri.org/
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world’s poorest people
No new digest content identified.

 

CARB-X [to 7 Nov 2020]
https://carb-x.org/
News
No new digest content identified.

 

CEPI – Coalition for Epidemic Preparedness Innovations [to 7 Nov 2020]
http://cepi.net/
Latest News
CEPI extends partnership with Clover to fund COVID-19 vaccine candidate through global Phase 2/3 study to licensure
:: CEPI to fund the development of Clover’s protein-based S-Trimer vaccine candidate through to licensure, including a global pivotal Phase 2/3 efficacy clinical study beginning before the end of 2020.
:: Agreement between CEPI and Clover anticipates that the vaccine – if proven to be safe and effective – will be made available for procurement and allocation through the COVAX Facility to those who need it most around the world.
:: CEPI’s total investment in S-Trimer will be up to $328 million, including $69.5 million previously announced.
OSLO, Norway and CHENGDU, China,  Nov 03, 2020— CEPI, the Coalition for Epidemic Preparedness Innovations, today announced that it will fund the development of the protein-based S-Trimer COVID-19 vaccine candidate by Sichuan Clover Biopharmaceuticals, Inc (China) (“Clover”) through a global pivotal Phase 2/3 efficacy clinical trial and to licensure in China and globally, if the vaccine is proven to be safe and effective…

 

EDCTP [to 7 Nov 2020]
http://www.edctp.org/
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
Latest news
No new digest content identified.

 

Emory Vaccine Center [to 7 Nov 2020]
http://www.vaccines.emory.edu/
Vaccine Center News
No new digest content identified.

 

European Medicines Agency [to 7 Nov 2020]
http://www.ema.europa.eu/ema/
News & Press Releases
News: International regulators and WHO join forces to address COVID-19 challenges
Last updated: 06/11/2020
[See COVID above for detail]

 

European Vaccine Initiative [to 7 Nov 2020]
http://www.euvaccine.eu/
Latest News
EVI, Oct 29, 2020
Open call for Vaccine R&D services
Developing a vaccine is a time-consuming and complex process, requiring a combination of specialized skills and technical capacities not readily available at a single organization. To facilitate access to these skills and capacities, TRANSVAC2 offers high-quality technical services to support the development of prophylactic and therapeutic vaccines for both human and animal use. These services are not restricted to any disease area. Services will be offered free of charge, with few exceptions! Academic and non-academic research groups, SMEs and industries can apply!
Submit your application by December 15th, 2020! For further information on services available and how to apply please visit www.transvac.org

 

FDA [to 7 Nov 2020]
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/default.htm
Press Announcements /Selected Details
November 6, 2020 – Coronavirus (COVID-19) Update: FDA Authorizes First Test that Detects Neutralizing Antibodies from Recent or Prior SARS-CoV-2 Infection

November 3, 2020 – Coronavirus (COVID-19) Update: November 3, 2020

 

FDA – COVID-19 Vaccines [to 7 Nov 2020]
www.fda.gov/covid19vaccines
Upcoming Events
No new digest content identified.

 

Fondation Merieux [to 7 Nov 2020]
http://www.fondation-merieux.org/
News, Events
No new digest content identified.

 

Gavi [to 7 Nov 2020]
https://www.gavi.org/
News releases
COVAX Facility convenes first meeting of COVAX Shareholders Council
3 November 2020
[See COVAX above for detail]

 

GHIT Fund [to 7 Nov 2020]
https://www.ghitfund.org/newsroom/press
GHIT was set up in 2012 with the aim of developing new tools to tackle infectious diseases that No new digest content identified.

 

Global Fund [to 7 Nov 2020]
https://www.theglobalfund.org/en/news/
News/Updates
Removing Human Rights Barriers to Health: Findings and Lessons
04 November 2020
Programs to remove human rights barriers to HIV, TB and malaria services are essential to increasing the effectiveness of Global Fund grants. Such programs help to ensure health services reach those most affected by the three diseases. The Global Fund Strategy 2017-2022 recognizes and reaffirms this through its human rights objective.
Breaking Down Barriers initiative
As part of attaining this objective, the Global Fund’s Breaking Down Barriers initiative aims to dramatically scale up programs to remove these obstacles. The Global Fund has now published a summary of key findings of the baseline assessments undertaken as part of the initiative:
Breaking Down Barriers Initiative: Summary of Key Findings of the Baseline Assessments in 20 Countries [download in English]

 

Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [to 7 Nov 2020]
https://www.glopid-r.org/news/
News
GloPID-R appoints new Chair and Vice Chairs to lead the network’s Board
05/11/2020
GloPID-R is delighted to announce that Dr. Charu Kaushic has been appointed Chair of the network following the excellent work carried out by Prof. Yazdan Yazdanpanah over the past two years. Prof. Yazdanpanah will continue to serve GloPID-R as a Vice Chair.

BMC Medicine publishes ‘Ending COVID-19: progress and gaps in research – highlights of the July 2020 GloPID-R COVID-19 Research Synergies Meetings’
03/11/2020

 

Hilleman Laboratories [to 7 Nov 2020]
http://www.hillemanlabs.org/
No new digest content identified.

 

Human Vaccines Project [to 7 Nov 2020]
http://www.humanvaccinesproject.org/media/press-releases/
Press Releases
HVP COVID Report
What a COVID-19 Vaccine may Mean for Ageing Adults 
Interview with Wayne Koff, Ph.D., President and CEO
HVP Editor Kristen Jill Abboud recently discussed the state of COVID-19 vaccine research with Koff and asked him about the priorities for evaluating and deploying eventual vaccines in various populations, including the elderly.

 

IAVI [to 7 Nov 2020]
https://www.iavi.org/newsroom
PRESS RELEASES/FEATURES
November 6, 2020
Participant Enrollment Begins for Phase I Trial of IAVI-Merck COVID-19 Vaccine Candidate
A Phase I clinical trial of the IAVI-Merck (known as MSD outside the United States and Canada) SARS-CoV-2 vaccine candidate V590 has begun enrolling participants. The randomized, placebo-controlled double-blinded trial is being conducted at seven sites in the U.S. and will include up to 252 participants ages 18 and up, including seniors. This vaccine candidate uses the recombinant vesicular stomatitis virus (rVSV) technology that IAVI has developed through its long-standing research program on an rVSV-based HIV vaccine candidate as well as rVSV-based vaccines for other emerging infectious diseases such as Lassa fever and Marburg virus disease.

Merck is the sponsor of the trial, which is called V590-001. IAVI has partnered with Merck on trial design and site selection, and the IAVI Human Immunology Laboratory at Imperial College London is conducting a panel of immunogenicity assays to assess certain aspects of immune responses to the vaccine.
The study will assess the safety, tolerability, and immunogenicity (the level of antibodies that target the virus) of V590 compared to placebo…

 

 

International Coalition of Medicines Regulatory Authorities [ICMRA]
http://www.icmra.info/drupal/en/news
Selected Statements, Press Releases, Research
WHO-ICMRA joint statement on the need for improved global regulatory alignment on COVID-19 medicines and vaccines
6 November 2020 – Statement
[See Milestones above for detail]

 

 

International Generic and Biosimilar Medicines Association [IGBA]
https://www.igbamedicines.org/
News
Global Biosimilars Week: Message of the IGBA Chair (November 2020) [Video]

 

 

IFFIm
http://www.iffim.org/
Press Releases/Announcements
No new digest content identified.

 

IFRC [to 7 Nov 2020]
http://media.ifrc.org/ifrc/news/press-releases/
Selected Press Releases, Announcements
No new digest content identified.

 

IRC International Rescue Committee [to 7 Nov 2020]
http://www.rescue.org/press-release-index
Media highlights [Selected]
No new digest content identified.

 

IVAC [to 7 Nov 2020]
https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html
Updates; Events
No new digest content identified.

 

IVI [to 7 Nov 2020]
http://www.ivi.int/
Selected IVI News, Announcements, Events
Webinar on AMR – Evidence to Action: Advancing the Antimicrobial Resistance agenda during a pandemic
Invitation for Webinar on “Evidence to Action: Advancing the Antimicrobial Resistance agenda during a pandemic”
You are invited to the Webinar on “Evidence to Action: Advancing the Antimicrobial Resistance agenda during a pandemic” on the 3rd of December 2020.

 

JEE Alliance [to 7 Nov 2020]
https://www.jeealliance.org/
Selected News and Events
No new digest content identified.

 

MSF/Médecins Sans Frontières [to 7 Nov 2020]
http://www.msf.org/
Latest [Selected Announcements]
DRC Ebola outbreaks
New strategies at work in eleventh Ebola outbreak in DRC
Interview 4 Nov 2020

Mozambique
Urgent assistance needed for hundreds of thousands of people displaced by viol…
Press Release 3 Nov 2020

South Sudan
Urgent vaccination campaign needed to stop spread of measles in Pibor
Press Release 3 Nov 2020
Juba, South Sudan ─ Two months into a measles outbreak in Pibor town in the Greater Pibor Administrative Area, the spread of the highly contagious and life-threatening illness is a severe growing crisis. Médecins Sans Frontières (MSF) calls on all health organisations to urgently launch a reactive vaccination campaign to curb the outbreak.
On 18 August 2020, MSF treated the first patient for suspected measles in Pibor town, eastern South Sudan. By the end of October, teams had treated over 250 children.
“We believe measles is now widespread and getting out of control. It is especially concerning that the Greater Pibor Administrative Area is flooded and in emergency. We started with four, then six and then 18 isolation beds,” says MSF’s Dr Adelard Shyaka. “At the moment we have 30 children with severe measles receiving treatment in our health facility.”…

 

National Vaccine Program Office – U.S. HHS [to 7 Nov 2020]
https://www.hhs.gov/vaccines/about/index.html
No new digest content identified.

 

NIH [to 7 Nov 2020]
http://www.nih.gov/news-events/news-releases
Selected News Releases
No new digest content identified.

 

PATH [to 7 Nov 2020]
https://www.path.org/media-center/
Press Release
No new digest content identified.

 

Sabin Vaccine Institute [to 7 Nov 2020]
http://www.sabin.org/updates/pressreleases
Statements and Press Releases
No new digest content identified.

 

UNAIDS [to 7 Nov 2020]
http://www.unaids.org/en
Selected Press Releases/Reports/Statements
6 November 2020
20–50–80 to reach 100 in Ukraine

3 November 2020
A tale of two Jamaican clinics during COVID-19

2 November 2020
Highly effective HIV prevention option not reaching those who need it

 

UNICEF [to 7 Nov 2020]
https://www.unicef.org/media/press-releases
Selected Press releases, Statements
Press release
11/06/2020
UNICEF alarmed by spike in school attacks in Cameroon
UNICEF calls on all parties to protect all children, at school or in their communities and to uphold the principles of the Safe Schools Declaration, which calls for stopping attacks on schools, education facilities and personnel

Press release
11/06/2020
UNICEF and WHO call for emergency action to avert major measles and polio epidemics
As COVID-19 disrupts immunizations, urgent action needed to protect most vulnerable children from deadly and debilitating diseases
[See Milestones above for detail]

Press release
11/05/2020
More than 1.5 million children at risk due to the impact of Tropical Storm ETA in Honduras- UNICEF

Statement
11/05/2020
At least five children and two aid workers killed in a renewed wave of violence in north-west Syria
Statement from Ted Chaiban, UNICEF Regional Director for the Middle East and North Africa

Press release
11/05/2020
UNICEF and WHO sound the alarm over 250 000 children at risk of vaccine-preventable diseases in Libya
TRIPOLI, Libya, 5 November 2020 – UNICEF and WHO are extremely concerned over severe shortages of critical vaccines in Libya that threaten the health of the country’s children. Over the past 7 months, unprecedented vaccine shortages in the country have disrupted children’s immunization schedules and put them at risk of disease and death.
There has been an alarming decline in the number of children receiving life-saving vaccines globally. In Libya, this decline is a direct result of the COVID-19 pandemic, which has led to the closure of international borders, movement restrictions, and delays procuring and distributing vaccines. Many vaccination centres have been forced to close due to shortages of personal protective equipment for health workers.
A recent assessment of 200 of Libya’s 700 vaccine sites, carried out by the National Centre of Disease Control with the support of UNICEF and WHO, showed that all 200 sites had stockouts of BCG vaccine and extremely limited quantities of hexavalent vaccine…

Press release
11/03/2020
Nearly half a million children in Nicaragua at risk from Hurricane Eta

 

Unitaid [to 7 Nov 2020]
https://unitaid.org/
Featured News
No new digest content identified.

 

Vaccination Acceptance Research Network (VARN) [to 7 Nov 2020]
https://vaccineacceptance.org/news.html#header1-2r
Announcements
No new digest content identified.

 

Vaccine Confidence Project [to 7 Nov 2020]
http://www.vaccineconfidence.org/
Research and Reports
No new digest content identified.

 

Vaccine Education Center – Children’s Hospital of Philadelphia [to 7 Nov 2020]
http://www.chop.edu/centers-programs/vaccine-education-center
No new digest content identified.

 

Wellcome Trust [to 7 Nov 2020]
https://wellcome.ac.uk/news
Opinion | 4 November 2020
Science can give us the tools to end the pandemic, but it needs funding
Jeremy Farrar, Director, Wellcome
Vaccines, tests and treatments, alongside well-equipped health systems, are the solutions to bringing the Covid-19 pandemic under control. But this won’t happen without urgent investment, explains Jeremy Farrar.  

 

The Wistar Institute [to 7 Nov 2020]
https://www.wistar.org/news/press-releases
Press Releases
No new digest content identified.

 

WFPHA: World Federation of Public Health Associations [to 7 Nov 2020]
https://www.wfpha.org/
Latest News
Major National Barriers to Climate Change Adaptation for Public Health
Nov 6, 2020
Major National Barriers to Climate Change Adaptation for Public Health – What are the major government constraints to enactment and implementation of public health-targeted climate change adaptation (CCA) strategies? According to a recent study…

Call for Case Studies on Responses to COVID-19 Aimed at Improving and Sustaining Health Equity
Nov 6, 2020
Call for Case Studies on Responses to COVID-19 Aimed at Improving and Sustaining Health Equity – World Health Organisation (WHO) in collaboration with the Sustainable Health Equity Movement (SHEM) initiative is seeking submissions of case studies that…

Oral Health for Children: A Human Right
Nov 2, 2020
Oral Health for Children: A Human Right – Every child should have good oral health as a basic human right. The World Federation of Public Health Associations (WFPHA) has produced 1 webinar to pinpoint: The global challenge of child oral health Why is…

 

World Organisation for Animal Health (OIE) [to 7 Nov 2020]
https://www.oie.int/en/for-the-media/press-releases/2020/
Press Releases
No new digest content identified.

 

 

::::::

 

ARM [Alliance for Regenerative Medicine] [to 7 Nov 2020]
https://alliancerm.org/press-releases/
Press Releases
No new digest content identified.

 

BIO [to 7 Nov 2020]
https://www.bio.org/press-releases
Press Releases
No new digest content identified.

 

DCVMN – Developing Country Vaccine Manufacturers Network [to 7 Nov 2020]
http://www.dcvmn.org/
News; Upcoming events
DCVMN manufacturers trigger successful Collaborative Registration Procedure (CRP) for WHO Prequalified Vaccines in Developing Countries
Geneva, 03nd November 2020 – Encouraged by open dialogue between WHO and DCVMN, vaccine manufacturers are actively pursuing the WHO Collaborative Registration Procedure: three companies – Biological E Ldt., Bharat Biotech International Ltd. and Serum Institute of India Pvt. Ltd.- were successful in registering their respective new WHO pre-qualified vaccines in eight developing countries: Democratic Republic of Congo, Eritrea, Ghana, Malaysia, Malawi, Nigeria, Sierra Leone, and Zambia.

The Collaborative Registration Procedure (CRP) was launched in 2013 to facilitate and accelerate the registration process for WHO-prequalified medicines and vaccines in 43 CRP-adopting countries [1]. It is based on information sharing between WHO prequalification services and National Regulatory Authorities (NRAs) by leveraging assessment and inspection reports of WHO prequalification, and thereby eliminating duplicative regulatory tasks, for in-country registration of quality-assured products, contributing to their wider availability. This procedure helps harmonize submissions and streamline the licensure process in many developing countries.

There has been a positive change in the registration process for WHO Prequalified vaccines during past few months [2]. The overall process has proceeded well within the stipulated 90 days period, likely due to the active consultation between NRA’s and WHO-CRP team, although the greater success of achieving maximum registrations through CRP is yet to come.
DCVMN calls for further support from governments to increase the value of WHO-Prequalification of vaccines towards accelerated global access goals.

1https://extranet.who.int/pqweb/medicines/collaborative-registration-faster-registration
[2https://www.who.int/pq-vector-control/resources/orient_crp.pdf?ua=1

 

ICBA – International Council of Biotechnology Associations [to 7 Nov 2020]
https://internationalbiotech.org/news/
News
No new digest content identified.

 

IFPMA [to 7 Nov 2020]
http://www.ifpma.org/resources/news-releases/
Selected Press Releases, Statements, Publications
No new digest content identified.

 

PhRMA [to 7 Nov 2020]
http://www.phrma.org/
Selected Press Releases, Statements
Press Release
U.S. trade policy must prioritize American biopharmaceutical innovation and patient access
November 2, 2020
As the United States biopharmaceutical industry works around the clock to develop vaccines and treatments for COVID-19, it’s more important than ever that countries’ international trade policies facilitate patient access to innovative medicines. The pandemic has shed additional light on various countries’ unsustainable barriers that threaten availability, research and development of much-needed treatments and cures…